---
layout: default
title: SweetDeep: A Wearable AI Solution for Real-Time Non-Invasive Diabetes Screening
---

# SweetDeep: A Wearable AI Solution for Real-Time Non-Invasive Diabetes Screening

**arXiv**: [2512.03471v1](https://arxiv.org/abs/2512.03471) | [PDF](https://arxiv.org/pdf/2512.03471.pdf)

**ä½œè€…**: Ian Henriques, Lynda Elhassar, Sarvesh Relekar, Denis Walrave, Shayan Hassantabar, Vishu Ghanakota, Adel Laoui, Mahmoud Aich, Rafia Tir, Mohamed Zerguine, Samir Louafi, Moncef Kimouche, Emmanuel Cosson, Niraj K Jha

---

## ðŸ’¡ ä¸€å¥è¯è¦ç‚¹

**æå‡ºSweetDeepï¼Œä¸€ç§åŸºäºŽå¯ç©¿æˆ´è®¾å¤‡çš„è½»é‡ç¥žç»ç½‘ç»œï¼Œç”¨äºŽå®žæ—¶éžä¾µå…¥æ€§2åž‹ç³–å°¿ç—…ç­›æŸ¥ã€‚**

**å…³é”®è¯**: `å¯ç©¿æˆ´è®¾å¤‡` `ç³–å°¿ç—…ç­›æŸ¥` `è½»é‡ç¥žç»ç½‘ç»œ` `å®žæ—¶æ£€æµ‹` `éžä¾µå…¥æ€§ç›‘æµ‹`

## ðŸ“‹ æ ¸å¿ƒè¦ç‚¹

1. æ ¸å¿ƒé—®é¢˜ï¼šå…¨çƒ2åž‹ç³–å°¿ç—…å¢žé•¿éœ€å¯æ‰©å±•ã€ä½Žæˆæœ¬ç­›æŸ¥æ–¹æ³•ï¼ŒçŽ°æœ‰ç”ŸåŒ–æ£€æµ‹ä¾µå…¥æ€§å¼ºä¸”æ˜‚è´µã€‚
2. æ–¹æ³•è¦ç‚¹ï¼šä½¿ç”¨ä¸‰æ˜ŸGalaxy Watch 7åœ¨è‡ªç”±ç”Ÿæ´»æ¡ä»¶ä¸‹æ”¶é›†285åå‚ä¸Žè€…çš„ç”Ÿç†å’Œäººå£æ•°æ®ï¼Œè®­ç»ƒå°‘äºŽ3000å‚æ•°çš„ç´§å‡‘ç¥žç»ç½‘ç»œã€‚
3. å®žéªŒæˆ–æ•ˆæžœï¼šåœ¨ä¸‰æŠ˜äº¤å‰éªŒè¯ä¸­è¾¾åˆ°82.5%æ‚£è€…çº§å‡†ç¡®çŽ‡ï¼Œå…è®¸æ¨¡åž‹åœ¨ä½Žç½®ä¿¡åº¦é¢„æµ‹ä¸Šå¼ƒæƒåŽï¼Œå‰©ä½™æ‚£è€…å‡†ç¡®çŽ‡æå‡è‡³84.5%ã€‚

## ðŸ“„ æ‘˜è¦ï¼ˆåŽŸæ–‡ï¼‰

> The global rise in type 2 diabetes underscores the need for scalable and cost-effective screening methods. Current diagnosis requires biochemical assays, which are invasive and costly. Advances in consumer wearables have enabled early explorations of machine learning-based disease detection, but prior studies were limited to controlled settings. We present SweetDeep, a compact neural network trained on physiological and demographic data from 285 (diabetic and non-diabetic) participants in the EU and MENA regions, collected using Samsung Galaxy Watch 7 devices in free-living conditions over six days. Each participant contributed multiple 2-minute sensor recordings per day, totaling approximately 20 recordings per individual. Despite comprising fewer than 3,000 parameters, SweetDeep achieves 82.5% patient-level accuracy (82.1% macro-F1, 79.7% sensitivity, 84.6% specificity) under three-fold cross-validation, with an expected calibration error of 5.5%. Allowing the model to abstain on less than 10% of low-confidence patient predictions yields an accuracy of 84.5% on the remaining patients. These findings demonstrate that combining engineered features with lightweight architectures can support accurate, rapid, and generalizable detection of type 2 diabetes in real-world wearable settings.

